

H1036-280 Humana Fully Integrated Florida prior authorization and notification list

Effective date: 01/01/2026

Revision Date: 04/29/2026

We have updated our prior authorization and notification list for H1036-280 Humana Fully Integrated Florida (health maintenance organization Dual Eligible Specials Need Plan [HMO D-SNP]) plans.

Please note the term “prior authorization” (preauthorization, precertification), when used in this communication, is defined as a process through which the healthcare provider is required to obtain advance approval from the plan as to whether an item or service will be covered.

The list details medications (i.e., medications that are delivered in the provider’s office, clinic, outpatient or home setting) that require prior authorization before being provided or administered. Services must be provided according to Medicare coverage guidelines established by the Centers for Medicare & Medicaid Services (CMS). According to the guidelines, all medical care, services, supplies and equipment must be medically necessary. You can review Medicare coverage guidelines [on the CMS website](#).

To view Humana’s Medical and Pharmacy Coverage Policies, please visit [Humana's Medical and Pharmacy Coverage Policies website](#).

Investigational and experimental procedures and devices usually are not covered benefits. Please consult the patient’s Evidence of Coverage or contact Humana for confirmation of coverage.

Please note that certain services may not be covered under the member’s plan.

Important notes:

Humana Medicare Advantage (MA) HMO: The full list of prior authorization requirements applies to patients with Humana MA HMO and HMO point-of-service (HMO POS) coverage. Healthcare providers who participate in an independent practice association (IPA) or other risk network with delegated services are subject to the prior authorization list (PAL) and should refer to their IPA or risk network for guidance on processing their requests. Exclusions may change, so please refer to [Humana's provider website](#) for the most up-to-date information.

All Humana MA plans: For procedures or services that are investigational or experimental (or that may have limited benefit coverage), or to learn if Humana will pay for a service, you can request an advance coverage determination (ACD) on behalf of the patient prior to providing the service. You may be contacted if additional information is needed.

ACDs for medications on the list can be initiated by submitting a fax or phone request: Submit by phone at



* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

** Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to transplant@humana.com.

866-461-7273 (TTY: 711), Monday – Friday, 8 a.m. – 11 p.m., Eastern time, or by fax to 888-447-3430. To prevent disruption of care, Humana does not require prior authorization for basic Medicare benefits during the first 90 days of a new member’s enrollment for active courses of treatment that started prior to enrollment. Humana may review services furnished during an active course of treatment against permissible coverage criteria when determining payment. To ensure appropriate claim payment, please include the modifier based on Humana’s Medicare Advantage Payment Policy (CP2023011), which can be found on [Humana's claims payment policies website](#), or include medical records with evidence that the member is in an active course of treatment.

Additional information related to step therapy for Medicare Part B medications:

Humana’s Medicare Part B Step Therapy Preferred Drug List (PDL), which includes background information about the program and a comprehensive list of preferred and nonpreferred medications, is available at [Humana's provider prior authorization notification lists website](#).

Some step therapy strategies for Medicare Advantage prescription drug plans may require a trial of a preferred medication across different benefits, such as Medicare Part B and Part D. Details regarding these cross-benefit strategies can be found on Humana’s Part B Step Therapy PDL, which is available on [Humana's provider prior authorization notification lists website](#).

Humana’s Part B Step Therapy PDL should be reviewed in conjunction with Humana's coverage policies, which are accessible on Humana’s [Medical and Pharmacy Coverage Policies website](#).

The designation of preferred status does not guarantee exemption from step therapy requirements. Please refer to the specific criteria contained in our coverage criteria policies, which is available on Humana’s [Medical and Pharmacy Coverage Policies website](#). Affected medications are noted with a step therapy indicator on the Medicare PAL at [Humana's provider prior authorization notification lists website](#).

If providers do not stock a preferred medication, they may be able to obtain the preferred medication from a pharmacy (e.g., pharmacy can ship the medication to the office). Please review our list of specialty and mail-order pharmacies at [Humana's mail-order webpage](#) to select a pharmacy that can provide the medication. A full list of pharmacies also is available on the [pharmacy finder tool](#).

If you have questions, please call us at 800-457-4708 (TTY: 711), daily, 8 a.m. – 8 p.m., Eastern time. However, please note that our automated phone system may answer your call during weekends and holidays from April 1 to Sept. 30. Please leave your name and phone number and we’ll call you back by the end of the next business day. For 24-hour service, please visit [Humana's website](#).

Please note that urgent/emergent services do not require referrals or prior authorizations.

Not obtaining prior authorization for a service could result in financial penalties for the practice and reduced benefits for the patient based on the healthcare provider’s contract and the patient’s Evidence of Coverage. Services or medications provided without prior authorization may be subject to retrospective medical necessity



* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

** Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to transplant@humana.com.

review. We recommend that an individual practitioner making a specific request for services or medications verify benefits and prior authorization requirements with Humana prior to providing services.

Information required for a prior authorization request or notification may include, but is not limited to, the following:

- Patient name, date of birth and Humana member ID number
- Date of actual service or hospital admission
- Healthcare Common Procedure Coding System (HCPCS) code(s) and diagnosis codes (primary and secondary) (up to a maximum of 6 per authorization request)
- Service location
 - Inpatient (acute hospital, skilled nursing or hospice)
 - Outpatient (telehealth, office, home, off-campus outpatient hospital, on-campus outpatient hospital or ambulatory surgery center)
- Tax Identification Number (TIN), National Provider Identifier (NPI) of facility where service is being rendered, and TIN and NPI number of the provider performing the service
- Caller/requester name and phone number and attending provider's phone number
- Relevant clinical information

Submitting all relevant clinical information at the time of the request will help expedite determination. If additional clinical information is required, a Humana representative will request the specific information needed to complete the authorization process.

How to request prior authorization:

Except where noted in the list below, prior authorization for medications may be initiated in one of 3 ways:

- Online: [CoverMyMeds](#)
- Phone number: 866-461-7273 (TTY: 711), Monday – Friday, 8 a.m. – 11 p.m., Eastern time
- Fax number: 888-447-3430 (Request forms are available on Humana's [prior authorization for professionally administered drugs website](#).)

The list below is subject to change with notification and may be modified throughout the year for additions of new-to-market medications or step therapy requirements for medications without notification by United States Postal Service mail.



* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

** Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to transplant@humana.com.

H1036-280 Humana Fully Integrated Florida (HMO D-SNP) prior authorization and notification list
[Access the fax forms](#) to request preauthorization or provide notification

| Brand medication name | Generic medication name | Billing Codes |
|----------------------------------|---|---------------------|
| Abecma intravenous suspension †† | idecabtagene vicleucel †† | Q2055 |
| Abraxane ** ‡ | paclitaxel-nab ** ‡ | J9264 |
| Actemra IV ** | tocilizumab ** | J3262 |
| Adakveo | crizanlizumab-tmca | J0791 |
| Adcetris | brentuximab vedotin | J9042 |
| Adstiladrin | nadofaragene firadenovec-vncg | J9029 |
| Aduhelm | aducanumab-avwa | J0172 |
| Adzynma | ADAMTS13, recombinant-krhn | J7171 |
| Akynzeo IV | fosnetupitant and palonosetron | J1454 |
| Aldurazyme | laronidase | J1931 |
| Alimta ‡ | pemetrexed ‡ | J9305 |
| Alyglo ** | immune globulin intravenous, human-stwk ** | J1552 |
| Alymsys ** | bevacizumab-maly ** | Q5126 |
| Amondys-45 | casimersen | J1426 |
| Amtagvi †† ‡ | lifileucel †† ‡ | C9399, J3490, J9999 |
| Amvuttra | vutrisiran | J0225 |
| Anktiva | nogapendekin alfa inbakicept-pmIn | J9028 |
| Aphexda | motixafortide | J2277 |
| Aralast NP ** ‡ | alpha 1-proteinase inhibitor ** ‡ | J0256 |
| Aranesp ** | darbepoetin alfa ** | J0881 |
| Asceniv ** | immune globulin ** | J1554 |



* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

** Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to transplant@humana.com.

H1036-280 Humana Fully Integrated Florida (HMO D-SNP) prior authorization and notification list
[Access the fax forms](#) to request preauthorization or provide notification

| Brand medication name | Generic medication name | Billing Codes |
|--|------------------------------|---------------------|
| Asparlas | calaspargase pegol-mknl | J9118 |
| Aucatzyl †† | obecabtagene autoleucl †† | Q2058 |
| Aukelso * ** ‡ | denosumab-kyqq * ** ‡ | Q5161 |
| Avastin ** (Auth only required for Oncology/Chemo use) | bevacizumab ** | J9035, C9257 |
| Aveed | testosterone undecanoate | J3145 |
| Avlayah * † ‡ | tividenofusp alfa-eknm * † ‡ | C9399, J3490, J3590 |
| Avsola ** | infliximab-axxq ** | Q5121 |
| Avtozma IV ** ‡ | tocilizumab-anoh ** ‡ | Q5156 |
| Axtle ‡ | pemetrexed ‡ | J9292 |
| Azedra | ibogenguane l 131 | A9590 |
| Bavencio | avelumab | J9023 |
| Beizray | docetaxel-albumin | J9174 |
| Beleodaq | belinostat | J9032 |
| Belrapzo ‡ | bendamustine hydrochloride ‡ | J9036 |
| Bendamustine (Apotex) | bendamustine hydrochloride | J9058 |
| Bendamustine (Baxter) | bendamustine hydrochloride | J9059 |
| Bendamustine ‡ | bendamustine hydrochloride ‡ | J9036 |
| Bendeka | bendamustine hydrochloride | J9034 |
| Benlysta | belimumab | J0490 |
| Beovu ** | brovacizumab-dbll ** | J0179 |
| Berinerter ** | C1 esterase inhibitor ** | J0597 |



* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

** Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to transplant@humana.com.

H1036-280 Humana Fully Integrated Florida (HMO D-SNP) prior authorization and notification list
[Access the fax forms](#) to request preauthorization or provide notification

| Brand medication name | Generic medication name | Billing Codes |
|-----------------------------|---|----------------------------|
| Besponsa | inotuzumab ozogamicin | J9229 |
| Bildyos ** ‡ | denosumab-nxxp ** ‡ | Q5162 |
| Bilprevda ** ‡ | denosumab-nxxp ** ‡ | Q5162 |
| Bivigam ** | immune globulin ** | J1556 |
| Bizengri | zenocutuzumab-zbco | J9382 |
| Bkemv IV ** | eculizumab-aeeb ** | Q5152 |
| Blenrep ‡ | belantamab mafodotin-blmf ‡ | C9399, J3490, J3590, J9999 |
| Blincyto | blinatumomab | J9039 |
| Bomynta ** ‡ | denosumab-bnht ** ‡ | Q5158 |
| bortezomib (Dr. Reddy's) | bortezomib | J9046 |
| bortezomib (Fresenius kabi) | bortezomib | J9048 |
| bortezomib (Hospira) | bortezomib | J9049 |
| bortezomib (Maia) | bortezomib | J9051 |
| bortezomib ‡ | bortezomib ‡ | J9041 |
| Boruzu | bortezomib | J9054 |
| Bosaya * ** ‡ | denosumab-kyqq * ** ‡ | Q5161 |
| Botox | onabotulinumtoxinA | J0585 |
| Breyanzi †† ‡ | lisocabtagene maraleucel †† ‡ | Q2054 |
| Brineura | cerliponase alfa | J0567 |
| Briumvi ** | ublrituximab-xiiv ** | J2329 |
| Byooviz ** | ranibizumab-nuna intravitreal solution ** | Q5124 |



* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

** Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to transplant@humana.com.

H1036-280 Humana Fully Integrated Florida (HMO D-SNP) prior authorization and notification list
[Access the fax forms](#) to request preauthorization or provide notification

| Brand medication name | Generic medication name | Billing Codes |
|-----------------------|------------------------------------|---------------|
| Carvykti †† | ciltacabtagene autoleucel †† | Q2056 |
| Casgevvy †† | exagamglogene autotemcel †† | J3392 |
| Cerezyme ** | imiglucerase ** | J1786 |
| Cimzia ** | certolizumab pegol ** | J0717 |
| Cinqair | reslizumab | J2786 |
| Cinryze ** | C1 esterase inhibitor (human) ** | J0598 |
| Columvi | glofitamab-gxbm | J9286 |
| Conexence ** ‡ | denosumab-bnht ** ‡ | Q5158 |
| Cosela | trilaciclib | J1448 |
| Cosentyx IV ** | secukinumab ** | J3247 |
| Crysvita | burosumab-twza | J0584 |
| Cutaquig ** | immune globulin ** | J1551 |
| Cuvitru ** | immune globulin ** | J1555 |
| Cyramza | ramucirumab | J9308 |
| Danyelza | naxitamab-gqgk | J9348 |
| Darzalex | daratumumab | J9145 |
| Darzalex Faspro | daratumumab and hyaluronidase-fihj | J9144 |
| Datroway | datopotamab deruxtecan | J9011 |
| Dawnzera ** ‡ | donidalorsen ** ‡ | C9399, J3490 |
| Daxxify | daxibotulinumtoxinA-lanm | J0589 |
| Defitelio ‡ | defibrotide sodium ‡ | C9399, J3490 |
| Docivyx | docetaxel | J9172 |



* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

** Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to transplant@humana.com.

H1036-280 Humana Fully Integrated Florida (HMO D-SNP) prior authorization and notification list
[Access the fax forms](#) to request preauthorization or provide notification

| Brand medication name | Generic medication name | Billing Codes |
|-----------------------|------------------------------------|-----------------------------------|
| Doxil | doxorubicin HCL liposome injection | Q2050 |
| Durysta | bimatoprost implant | J7351 |
| Dysport | abobotulinumtoxin A | J0586 |
| Elahere | mirvetuximab soravtansine-gynx | J9063 |
| Elaprase | idursulfase | J1743 |
| Elelyso | taliglucerase alfa | J3060 |
| Elevidys | delandistrogene moxeparvovec-rokl | J1413 |
| Elfabrio IV | pegunigalsidase alfa-iwxj | J2508 |
| Elrexfio | elranatamab-bcmm | J1323 |
| Elzonris | tagraxofusp-erzs | J9269 |
| Empaveli † | pegcetacoplan † | C9399, J3490 |
| Empliciti | elotuzumab | J9176 |
| Emrelis IV | telisotuzumab vedotin-tllv | J9326 |
| Encelto | revakinagene taroretcel-lwey | J3403 |
| Enhertu | fam-trastuzumab deruxtecan-nxki | J9358 |
| Enjaymo | sutimlimab-jome | J1302 |
| Enoby ** † | denosumab-qbde ** † | C9399, J3490, J3590, J9999 |
| Enspryng † | satralizumab-mwge † | C9399, J3590, J3490 |
| Entyvio IV ** | vedolizumab ** | J3380 |
| Epkiny | epcoritamab-bysp | J9321 |
| Epogen ** † | epoetin alfa ** † | J0885 |
| Epysqli IV ** | eculizumab-aagh ** | Q5151 |



* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

** Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to transplant@humana.com.

H1036-280 Humana Fully Integrated Florida (HMO D-SNP) prior authorization and notification list
[Access the fax forms](#) to request preauthorization or provide notification

| Brand medication name | Generic medication name | Billing Codes |
|------------------------------|---|---------------------|
| Erbitux | cetuximab | J9055 |
| Erwinase ‡ | crisantaspase ‡ | J9019 |
| Euflexxa ** | sodium hyaluronate ** | J7323 |
| Evenity ** | romosozumab-aqqg ** | J3111 |
| Evkeeza ** | evinacumab-dgnb ** | J1305 |
| Exdensur ** ‡ | depemokimab-ulaa ** ‡ | C9399, J3490, J3590 |
| Exondys 51 | eteplirsen | J1428 |
| Eylea ** | aflibercept ** | J0178 |
| Eylea HD ** | aflibercept ** | J0177 |
| Fabrazyme | agalsidase beta | J0180 |
| Fasenra | benralizumab | J0517 |
| Faslodex | fulvestrant | J9395 |
| Feraheme ** | ferumoxytol ** | Q0138 |
| Firazyr ** ‡ | icatibant ** ‡ | J1744 |
| Flebogamma DIF ‡ | immune globulin ‡ | J1572 |
| Folotyn ‡ | pralatrexate ‡ | J9307 |
| Fulphila | pegfilgrastim-jmdb | Q5108 |
| fulvestrant (Fresenius kabi) | fulvestrant | J9394 |
| fulvestrant (Teva) | fulvestrant | J9393 |
| Fyarro | sirolimus protein-bound particles for injectable suspension | J9331 |
| Fynetra ** | pegfilgrastim-pbbk ** | Q5130 |



* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

** Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to transplant@humana.com.

H1036-280 Humana Fully Integrated Florida (HMO D-SNP) prior authorization and notification list
[Access the fax forms](#) to request preauthorization or provide notification

| Brand medication name | Generic medication name | Billing Codes |
|-----------------------|--|---------------|
| GamaSTAN ‡ | immune globulin ‡ | J1460, J1560 |
| GamaSTAN S/D ‡ | immune globulin ‡ | J1460, J1560 |
| Gamifant | emapalumab-lzsg | J9210 |
| Gammagard ‡ | immune globulin ‡ | J1569 |
| Gammagard ERC ‡ | immune globulin, human ‡ | J1566, J1569 |
| Gammagard S/D ‡ | immune globulin ‡ | J1566 |
| Gammaked ‡ | immune globulin ‡ | J1561 |
| Gammaplex ** | immune globulin ** | J1557 |
| Gamunex-C ‡ | immune globulin ‡ | J1561 |
| Gazyva | obinutuzumab | J9301 |
| Gel-One ** | sodium hyaluronate ** | J7326 |
| Gelsyn-3 ** | sodium hyaluronate ** | J7328 |
| Genvisc 850 ** | sodium hyaluronate ** | J7320 |
| Givlaari | givosiran | J0223 |
| Glassia ** | alpha 1-proteinase inhibitor ** | J0257 |
| Granix ** | tbo-filgrastim ** | J1447 |
| Haegarda | c1 esterase inhibitor subcutaneous | J0599 |
| Herceptin (IV) ** | trastuzumab ** | J9355 |
| Herceptin Hylecta ** | trastuzumab and hyaluronidase-oysk ** | J9356 |
| Hercessi IV ** | trastuzumab-strf ** | Q5146 |
| Herzuma ** | trastuzumab-pkrb ** | Q5113 |



* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

** Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to transplant@humana.com.

H1036-280 Humana Fully Integrated Florida (HMO D-SNP) prior authorization and notification list
[Access the fax forms](#) to request preauthorization or provide notification

| Brand medication name | Generic medication name | Billing Codes |
|-------------------------------------|---------------------------------|---------------------|
| Hizentra | immune globulin | J1559 |
| Hyalgan ** ‡ | sodium hyaluronate ** ‡ | J7321 |
| Hymovis ** ‡ | sodium hyaluronate ** ‡ | J7322 |
| Hymovis ONE ** ‡ | HYALURONATE ** ‡ | C9399, J3490 |
| Hyqvia ** | immune globulin ** | J1575 |
| iDose TR 75mcg intracameral implant | travoprost intracameral implant | J7355 |
| Ilaris | canakinumab | J0638 |
| Ilumya ** | tildrakizumab-asmn ** | J3245 |
| Iluvien | fluocinolone acetonide | J7313 |
| Imaavy ** | nipocalimab-aahu ** | J9256 |
| Imdelltra | tarlatamab-dlle | J9026 |
| Imfinzi ** | durvalumab ** | J9173 |
| Imjudo ** | tremelimumab-actl ** | J9347 |
| Imlygic | talimogene laherparepvec | J9325 |
| Imuldosa IV ** ‡ | ustekinumab-srlf ** ‡ | Q5098 |
| Inflectra | infliximab-dyyb | Q5103 |
| Infliximab | infliximab | J1745 |
| Injectafer ** | ferric carboxymaltose ** | J1439 |
| Inlexzo intravesical system | gemcitabine | J9183 |
| Istodax | romidepsin | J9319 |
| Itvisma ‡ | onasemnogene abeparvovec-brve ‡ | C9309, J3490, J3590 |



* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

** Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to transplant@humana.com.

H1036-280 Humana Fully Integrated Florida (HMO D-SNP) prior authorization and notification list
[Access the fax forms](#) to request preauthorization or provide notification

| Brand medication name | Generic medication name | Billing Codes |
|-----------------------|--|---------------------|
| Ixempra | ixabepilone | J9207 |
| Izervay | avacincaptad pegol intravitreal solution | J2782 |
| Jelmyto ‡ | mitomycin ‡ | J9281 |
| Jemperli | dostarlimab-gxly | J9272 |
| Jevtana | cabazitaxel | J9043 |
| Jobevne ** | bevacizumab-nwgd ** | Q5160 |
| Jubbonti ‡ | denosumab-bbdz ‡ | Q5136 |
| Kadcyla | ado-trastuzumab emtansine | J9354 |
| Kalbitor ** | ecallantide ** | J1290 |
| Kanjinti | trastuzumab-anns | Q5117 |
| Kanuma | sebelipase alfa | J2840 |
| Kebilidi †† ‡ | eladocogene exuparvec-tneq †† ‡ | C9399, J3490, J3590 |
| Keytruda ** | pembrolizumab ** | J9271 |
| Keytruda Qlex ** | pembrolizumab and berahyaluronidase alfa-pmph ** | J9277 |
| Khapzory | levoleucovorin | J0642 |
| Kimmtrak | tebentafusp-tebn | J9274 |
| Kisunla | donanemab-azbt | J0175 |
| Korsuva | difelikefalin | J0879 |
| Krystexxa | pegloticase | J2507 |
| Kymriah †† | tisagenlecleucel †† | Q2042 |
| Kyprolis | carfilzomib | J9047 |



* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

** Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to transplant@humana.com.

H1036-280 Humana Fully Integrated Florida (HMO D-SNP) prior authorization and notification list
[Access the fax forms](#) to request preauthorization or provide notification

| Brand medication name | Generic medication name | Billing Codes |
|-----------------------|-------------------------------|---------------------|
| Kyxata | carboplatin | J9278 |
| Lamzedo | velmanase alfa-tycv | J0217 |
| Ianreotide (Cipla) | Ianreotide | J1932 |
| Ianreotide ‡ | Ianreotide ‡ | J1930 |
| Lantidra †† ‡ | donislecel-jujn †† ‡ | C9399, J3490, J3590 |
| Lemtrada ** | alemtuzumab ** | J0202 |
| Lenmeldy †† | atidarsagene autotemcel †† | J3391 |
| Leqembi | Iecanemab-irmb | J0174 |
| Leqembi Iqlik ‡ | Iecanemab-irmb ‡ | C9399, J3490, J3590 |
| Leqvio ** | inclisiran ** | J1306 |
| Leukine | sargramostim | J2820 |
| Levoleucovorin ‡ | levoleucovorin calcium ‡ | J0641 |
| Libtayo | cemiplimab-rwlc | J9119 |
| Loargys ‡ | pegzilarginase-nbln ‡ | C9399, J3490, J3590 |
| Loqtorzi | toripalimab-tpzi | J3263 |
| Lucentis ** | ranibizumab ** | J2778 |
| Lumizyme | alglucosidase alfa | J0221 |
| Lunsumio ‡ | mosunetuzumab-axgb ‡ | J9350 |
| Lunsumio Velo ‡ | mosunetuzumab-axgb ‡ | J9350 |
| Lutathera ** | lutetium Lu 177 dotatate ** | A9513 |
| Luxturna | voretigene neparvovec-rzyl | J3398 |
| Lyfgenia †† | lovotibeglogene autotemcel †† | J3394 |



* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

** Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to transplant@humana.com.

H1036-280 Humana Fully Integrated Florida (HMO D-SNP) prior authorization and notification list
[Access the fax forms](#) to request preauthorization or provide notification

| Brand medication name | Generic medication name | Billing Codes |
|-------------------------|---|----------------------------|
| Lymphir * | denileukin diftitox-cxdl * | J9161 |
| Lynozytic | linvoseltamab-gcpt | J9601 |
| Margenza | margetuximab-cmkb | J9353 |
| Mepsevii | vestronidase alfa-vjvk | J3397 |
| Mircera | methoxy polyethylene glycol - epoetin beta | J0888 |
| Monjuvi | tafasitamab-cxix | J9349 |
| Monoferic ** | ferric derisomaltose ** | J1437 |
| Mozobil ‡ | plerixafor ‡ | J2562 |
| Mvasi | bevacizumab-awwb | Q5107 |
| Mylotarg | gemtuzumab ozogamicin | J9203 |
| Myobloc | rimabotulinumtoxinB | J0587 |
| Naglazyme | galsulfase | J1458 |
| Neulasta ‡ | pegfilgrastim ‡ | J2506 |
| Neulasta Onpro ‡ | pegfilgrastim ‡ | J2506 |
| Neupogen ** | filgrastim ** | J1442 |
| Nexvazyme | avalglucosidase alfa-ngpt | J0219 |
| Ngenla ‡ | somatrogon-ghla ‡ | C9399, J3490, J3590 |
| Niktimvo IV | axatilimab-csfr | J9038 |
| Nivestym ** | filgrastim-aafi ** | Q5110 |
| Nplate | romiplostim | J2802 |
| Nucala | mepolizumab | J2182 |



* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

** Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to transplant@humana.com.

H1036-280 Humana Fully Integrated Florida (HMO D-SNP) prior authorization and notification list
[Access the fax forms](#) to request preauthorization or provide notification

| Brand medication name | Generic medication name | Billing Codes |
|-----------------------|---|---------------------|
| Nulibry | fosdenopterin | J1809 |
| Nypozi ** | filgrastim-txid ** | Q5148 |
| Nyvepria ** | pegfilgrastim-apgf ** | Q5122 |
| Ocrevus | ocrelizumab | J2350 |
| Ocrevus Zunovo | ocrelizumab and hyaluronidase-oscq | J2351 |
| Octagam | immune globulin | J1568 |
| Ogivri ** | trastuzumab-dkst ** | Q5114 |
| Omisirge †† ‡ | omidubicel-only †† ‡ | C9399, J3490, J3590 |
| OmvoH IV ** ‡ | mirikizumab-mrkz ** ‡ | J2267 |
| Onapgo SQ Cartridge ‡ | apomorphine hydrochloride ‡ | C9399, J3490 |
| Oncaspar | pegaspargase | J9266 |
| Onivyde | irinotecan liposome injection | J9205 |
| Onpattro | patisiran | J0222 |
| Ontruzant ** | trastuzumab-dttb ** | Q5112 |
| Opdivo ** | nivolumab ** | J9299 |
| Opdivo Qvantig | nivolumab hyaluronidase-nvhy | J9289 |
| Opdualag | nivolumab and relatlimab-rmbw injection | J9298 |
| Orencia IV ** | abatacept ** | J0129 |
| Osenvelt ** ‡ | denosumab-bmwo ** ‡ | Q5157 |
| Ospomyv ** ‡ | denosumab-dssb ** ‡ | Q5159 |
| Otulfi IV | ustekinumab-aaaz | Q9999 |



* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

** Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to transplant@humana.com.

H1036-280 Humana Fully Integrated Florida (HMO D-SNP) prior authorization and notification list
[Access the fax forms](#) to request preauthorization or provide notification

| Brand medication name | Generic medication name | Billing Codes |
|-------------------------------|---|---------------------|
| Oxlumo | lumasiran | J0224 |
| Ozurdex | dexamethasone intravitreal implant | J7312 |
| paclitaxel protein-bound ** ‡ | paclitaxel protein-bound ** ‡ | J9264 |
| Padcev | enfortumab vedotin-ejfv | J9177 |
| Palynziq ‡ | pegvaliase-pqpz ‡ | C9399, J3490, J3590 |
| Panhematin | hemin | J1640 |
| Panzyga ** | immune globulin ** | J1576 |
| Papzimeos | zopapogene imadenovec-drba | J3404 |
| Pavblu ** | aflibercept-ayyh ** | Q5147 |
| Pedmark IV solution | sodium thiosulfate | J0208 |
| Pemetrexed | pemetrexed | J9305 |
| Pemetrexed (Accord) | pemetrexed | J9296 |
| Pemetrexed (Bluepoint) | pemetrexed | J9322 |
| Pemetrexed (Sandoz) | pemetrexed | J9297 |
| Pemetrexed (Teva) | pemetrexed | J9314 |
| pemetrexed disodium (Hospira) | pemetrexed disodium | J9294 |
| pemetrexed ditromethamine | pemetrexed ditromethamine | J9323 |
| Pemfexy | pemetrexed injection | J9304 |
| Pemrydi RTU | pemetrexed | J9324 |
| Perjeta | pertuzumab | J9306 |
| Phesgo | pertuzumab, trastuzumab, and hyaluronidase-zzxf | J9316 |



* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

** Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to transplant@humana.com.

H1036-280 Humana Fully Integrated Florida (HMO D-SNP) prior authorization and notification list
[Access the fax forms](#) to request preauthorization or provide notification

| Brand medication name | Generic medication name | Billing Codes |
|-----------------------|---|----------------------------|
| Piasky ** | crovalimab-akkz ** | J1307 |
| plerixafor ‡ | plerixafor ‡ | J2562 |
| Pluvicto | lutetium Lu 177 vipivotide tetraxetan | A9607 |
| Polivy | polatuzumab vedotin-piiq | J9309 |
| Pombiliti | cipaglucoasidase alfa-atga | J1203 |
| Portrazza | necitumumab | J9295 |
| Poteligeo | mogamulizumab-kpkc | J9204 |
| pralatrexate IV ‡ | pralatrexate ‡ | J9307 |
| Prevymis IV ‡ | letermovir ‡ | C9399, J3490 |
| Prialt | ziconotide | J2278 |
| Privigen | immune globulin | J1459 |
| Procrit ‡ | epoetin alfa ‡ | J0885 |
| Prolastin-C ** ‡ | alpha 1-proteinase inhibitor ** ‡ | J0256 |
| Prolia | denosumab | J0897 |
| Provenge | sipuleucel-T | Q2043 |
| Pyzchiva IV ** | ustekinumab-ttwe ** | Q9997 |
| Qalsody | tofersen | J1304 |
| Qivigy ** ‡ | immune globulin intravenous, human-kthm ** ‡ | C9399, J3490, J3590, J1599 |
| Qutenza | capsaicin/skin cleanser | J7336 |
| Radicava | edaravone | J1301 |
| Reblozyl ** | luspatercept-aamt ** | J0896 |



* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

** Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to transplant@humana.com.

H1036-280 Humana Fully Integrated Florida (HMO D-SNP) prior authorization and notification list
[Access the fax forms](#) to request preauthorization or provide notification

| Brand medication name | Generic medication name | Billing Codes |
|-----------------------|---|----------------------------|
| Releuko ** | filgrastim-ayow injection ** | Q5125 |
| Remicade | infliximab | J1745 |
| Remodulin ‡ | treprostinil (injection) ‡ | J3285 |
| Renflexis ** | infliximab-abda ** | Q5104 |
| Retacrit | epoetin alfa-epbx | Q5106 |
| Rethymic †† ‡ | allogeneic processed thymus tissue- agdc †† ‡ | C9399, J3490, J3590 |
| Riabni ** | rituximab-arrx ** | Q5123 |
| Rituxan Hycela ** | rituximab; hyaluronidase human ** | J9311 |
| Rituxan IV ** | rituximab ** | J9312 |
| Rolvedon ** | eflapegrastim-xnst ** | J1449 |
| romidepsin | romidepsin | J9318 |
| Ruconest ** | C1 esterase inhibitor ** | J0596 |
| Ruxience ** | rituximab-pvvr ** | Q5119 |
| Rybrevant Faspro ‡ | amivantamab and hyaluronidase-lpuj ‡ | C9399, J3490, J3590, J9999 |
| Rybrevant IV | amivantamab-vmjw | J9061 |
| Rylaze | asparaginase erwinia chrysanthemi (recombinant)-rywn | J9021 |
| Ryoncil †† | remestemcel-L-rknd †† | J3402 |
| Ryplazim | plasminogen, human-tvmh | J2998 |
| Rystiggo ** | rozanolixizumab-noli ** | J9333 |
| Rytelo IV | imetelstat | J0870 |



* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

** Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to transplant@humana.com.

H1036-280 Humana Fully Integrated Florida (HMO D-SNP) prior authorization and notification list
[Access the fax forms](#) to request preauthorization or provide notification

| Brand medication name | Generic medication name | Billing Codes |
|-------------------------------|--------------------------------|---------------------|
| Ryzneuta ** | efbemalenograstim alfa-VUXW ** | J9361 |
| Sajazir ‡ | icatibant ‡ | J1744 |
| Sandostatin LAR | octreotide | J2353 |
| Saphnelo intravenous solution | anifrolumab-fnia | J0491 |
| Sarclisa | isatuximab-irfc | J9227 |
| Scenesse | afamelanotide | J7352 |
| Selarsdi IV ** ‡ | ustekinumab-aekn ** ‡ | Q9998 |
| Signifor LAR | pasireotide | J2502 |
| Simponi ARIA | golimumab | J1602 |
| Sinuva | mometasone furoate | J7402 |
| Skyrizi IV | risankizumab-rzaa | J2327 |
| Skysona †† | elivaldogene autotemcel †† | J3387 |
| Soliris ** | eculizumab ** | J1299 |
| Somatuline Depot ‡ | lanreotide ‡ | J1930 |
| Spevigo IV | spesolimab-sbzo | J1747 |
| Spinraza | nusinersen | J2326 |
| Starjemza IV ** ‡ | ustekinumab-hmny ** ‡ | C9399, J3490, J3590 |
| Stelara IV ‡ | ustekinumab ‡ | J3358 |
| Steqeyma IV ** | ustekinumab-stba ** | Q5099 |
| Stimufend ** | pegfilgrastim-fpgk ** | Q5127 |
| Stoboclo ** ‡ | denosumab-bmwo ** ‡ | Q5157 |
| Sustol | granisetron | J1627 |



* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

** Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to transplant@humana.com.

H1036-280 Humana Fully Integrated Florida (HMO D-SNP) prior authorization and notification list
[Access the fax forms](#) to request preauthorization or provide notification

| Brand medication name | Generic medication name | Billing Codes |
|---|---|---------------|
| Susvimo ** | ranibizumab ** | J2779 |
| Syfovre | pegcetacoplan | J2781 |
| SynoJoynt ** | 1% sodium hyaluronate ** | J7331 |
| Synribo | omacetaxine mepesuccinate | J9262 |
| Synvisc ** ‡ | hylan G-F 20 ** ‡ | J7325 |
| Takhzyro ** | lanadelumab-flyo ** | J0593 |
| Talvey | talquetamab-tgvs | J3055 |
| Tecartus †† | brexucabtagene autoeucel †† | Q2053 |
| Tecelra †† | afamitresgene autoleucel †† | Q2057 |
| Tecentriq ** | atezolizumab ** | J9022 |
| Tecentriq Hybreza ** | atezolizumab and hyaluronidase-tqjs ** | J9024 |
| Tecvayli | teclistamab-cqyv | J9380 |
| Tepezza | teprotumumab-trbw | J3241 |
| Tevimbra | tislelizumab-jsgr | J9329 |
| Tezspire ‡ | tezepelumab-ekko ‡ | J2356 |
| Tezspire subcutaneous pen injector ‡ | tezepelumab-ekko ‡ | J2356 |
| Thrombate III | antithrombin III | J7197 |
| Tivdak ** | tisotumab vedotin-tftv ** | J9273 |
| Tofidence IV ** | tocilizumab-bavi ** | Q5133 |
| Trazimera | trastuzumab-qyyp | Q5116 |
| Treanda | bendamustine hydrochloride | J9033 |



* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

** Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to transplant@humana.com.

H1036-280 Humana Fully Integrated Florida (HMO D-SNP) prior authorization and notification list
[Access the fax forms](#) to request preauthorization or provide notification

| Brand medication name | Generic medication name | Billing Codes |
|------------------------|-----------------------------|---------------|
| Tremfya IV ‡ | guselkumab ‡ | J1628 |
| Triluron ** | sodium hyaluronate ** | J7332 |
| Trisenox | arsenic trioxide | J9017 |
| TriVisc ** | sodium hyaluronate ** | J7329 |
| Trodelvy | sacituzumab govitecan-hziy | J9317 |
| Truxima ** | rituximab-abbs ** | Q5115 |
| Tyenne IV ** | tocilizumab-aazg ** | Q5135 |
| Tyruko | natalizumab-sztn | Q5134 |
| Tysabri ** | natalizumab ** | J2323 |
| Tyvaso | treprostinil (inhaled) | J7686 |
| Tzield | teplizumab-mzwv | J9381 |
| Udenyca ‡ | pegfilgrastim-cbqv ‡ | Q5111 |
| Udenyca Autoinjector ‡ | pegfilgrastim-cbqv ‡ | Q5111 |
| Udenyca Onbody ‡ | pegfilgrastim-cbqv ‡ | Q5111 |
| Ultomiris | ravulizumab-cwvz | J1303 |
| Unituxin ‡ | dinutuximab ‡ | C9399, J3490 |
| Unloxcyt * | cosibelimab-ipdl * | J9275 |
| Uplizna ** | inebilizumab-cdon ** | J1823 |
| Ustekinumab IV ** ‡ | ustekinumab ** ‡ | J3358 |
| Vabysmo ** | faricimab-svoa injection ** | J2777 |
| Valstar | valrubicin | J9357 |
| Vectibix | panitumumab | J9303 |



* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

** Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to transplant@humana.com.

H1036-280 Humana Fully Integrated Florida (HMO D-SNP) prior authorization and notification list
[Access the fax forms](#) to request preauthorization or provide notification

| Brand medication name | Generic medication name | Billing Codes |
|------------------------|--|---------------------|
| Vegzelma ** | bevacizumab-adcd ** | Q5129 |
| Velcade ‡ | bortezomib ‡ | J9041 |
| Veopoz | pozelimab-bbfg | J9376 |
| Viltepso | viltolarsen | J1427 |
| Vimizim | elosulfase alfa | J1322 |
| Visco-3 ** ‡ | sodium hyaluronate ** ‡ | J7321 |
| Vivimusta | bendamustine hydrochloride | J9056 |
| Vpriv ** | velaglucerase alfa ** | J3385 |
| Vyepti ** | eptinezumab-jjmr ** | J3032 |
| Vyjuvek | beremagene geperpavec-svdt | J3401 |
| Vyloy | zolbetuximab-clzb | J1326 |
| Vyondys 53 | golodirsen | J1429 |
| Vyvgart Hytrulo | efgartigimod alfa and hyaluronidase-qvfc | J9334 |
| Vyvgart IV | efgartigimod alfa-fcab | J9332 |
| Vyxeos | daunorubicin/cytarabine | J9153 |
| Wainua ‡ | eplontersen injection ‡ | C9399, J3490 |
| Wezlana IV ** | ustekinumab-auub ** | Q5138 |
| Wyost ** ‡ | denosumab-bbdz ** ‡ | Q5136 |
| Xembify | immune globulin | J1558 |
| Xenpozyme | olipudase alfa-rpcp | J0218 |
| Xeomin | incobotulinumtoxinA | J0588 |



* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

** Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to transplant@humana.com.

H1036-280 Humana Fully Integrated Florida (HMO D-SNP) prior authorization and notification list
[Access the fax forms](#) to request preauthorization or provide notification

| Brand medication name | Generic medication name | Billing Codes |
|-----------------------|---|----------------------------|
| Xgeva ** ‡ | denosumab ** ‡ | J0897 |
| Xipere | triamcinolone acetone | J3299 |
| Xofigo | radium Ra 223 dichloride | A9606 |
| Xolair | omalizumab | J2357 |
| Xtrenbo ** ‡ | denosumab-qbde ** ‡ | C9399, J3490, J3590, J9999 |
| Yartemlea ‡ | narsoplimab-wuug ‡ | C9399, J3490, J3590 |
| Yervoy ** | ipilimumab ** | J9228 |
| Yescarta †† | axicabtagene ciloleucel †† | Q2041 |
| Yesintek IV ‡ | ustekinumab-kfce ‡ | Q5100 |
| Yimmugo ** | immune globulin intravenous, human - dira ** | J1553 |
| Yondelis | trabectedin | J9352 |
| Zaltrap | ziv-aflibercept | J9400 |
| Zarxio | filgrastim-sndz | Q5101 |
| Zemaira ‡ | alpha 1-proteinase inhibitor ‡ | J0256 |
| Zepzelca | lurbinectedin | J9223 |
| Zevalin | ibritumomab tiuxetan | A9543 |
| Zevaskyn †† | prademagene zamikeracel †† | J3389 |
| Ziextenzo ** | pegfilgrastim-bmez ** | Q5120 |
| Ziihera | zanidatamab-hrii | J9276 |
| Zilretta ** | triamcinolone acetone ** | J3304 |
| Zirabev | bevacizumab-bvzr | Q5118 |



* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

** Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to transplant@humana.com.

H1036-280 Humana Fully Integrated Florida (HMO D-SNP) prior authorization and notification list
[Access the fax forms](#) to request preauthorization or provide notification

| Brand medication name | Generic medication name | Billing Codes |
|-----------------------|-------------------------------|---------------|
| Zoladex | goserelin acetate | J9202 |
| Zolgensma | onasemnogene abeparvovec-xioi | J3399 |
| Zusduri | mitomycin | J9282 |
| Zynlonta | loncastuximab tesirine-lpyl | J9359 |
| Zynteglo †† | betibeglogene autotemcel †† | J3393 |
| Zynyz | retifanlimab-dlwr | J9345 |



* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

** Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to transplant@humana.com.

| Blood-clotting Factors | | |
|-------------------------------|---|----------------------|
| Brand medication name | Generic medication name | Billing Codes |
| Advate † | antihemophilic factor, human recombinant † | J7192 |
| Adynovate | antihemophilic factor [recombinant], PEGylated | J7207 |
| Afstyla | antihemophilic factor (recombinant) single chain | J7210 |
| Alhemo ** | concizumab-mtci ** | J7173 |
| Alphanate | antihemophilic factor/von Willebrand factor complex [human] | J7186 |
| AlphaNine SD | coagulation factor IX [human] | J7193 |
| Alprolix | coagulation factor IX [recombinant] | J7201 |
| Altuviio | efanesoctocog alfa | J7214 |
| Benefix † | coagulation factor IX [recombinant] † | J7195 |
| Beqvez | fidanacogene elaparvovec-dzkt | J1414 |
| Coagadex | coagulation factor X [human] | J7175 |
| Corifact | factor XIII concentrate [human] | J7180 |
| Eloctate | antihemophilic factor [recombinant], Fc fusion protein | J7205 |
| Esperoct | antihemophilic factor (recombinant), glycopegylated-exei | J7204 |
| Feiba NF | anti-inhibitor coagulant complex | J7198 |
| Hemgenix | etranacogene dezaparvovec-drlb | J1411 |
| Hemlibra ** | emicizumab-kxwh ** | J7170 |
| Hemofil M † | antihemophilic factor [human] † | J7190 |



* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

** Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to transplant@humana.com.

| Blood-clotting Factors | | |
|-------------------------------|---|----------------------|
| Brand medication name | Generic medication name | Billing Codes |
| Humate-P | antihemophilic factor/von Willebrand factor complex [human] | J7187 |
| Hypnavzi ** | marstacimab-hncq ** | J7172 |
| Idelvion | coagulation factor IX (recombinant) | J7202 |
| Ixinity | coagulation factor IX [recombinant] | J7213 |
| Jivi | antihemophilic factor (recombinant), PEGylated-aucl | J7208 |
| Koate-DVI ‡ | antihemophilic factor [human] ‡ | J7190 |
| Kogenate FS ‡ | antihemophilic factor [recombinant] ‡ | J7192 |
| Kovaltry | antihemophilic factor [recombinant] | J7211 |
| NovoEight | turoctocog alfa | J7182 |
| NovoSeven RT | coagulation Factor VIIa, recombinant; eptacog alfa | J7189 |
| Nuwiq | simoctocog alfa | J7209 |
| Obizur | antihemophilic factor [recombinant], porcine sequence | J7188 |
| Profilnine | factor IX complex | J7194 |
| Qfitlia ** ‡ | fitusiran ** ‡ | J7174 |
| Rebinyon | Coagulation Factor IX [Recombinant], GlycoPEGylated | J7203 |
| Recombinate ‡ | antihemophilic factor [recombinant] ‡ | J7192 |
| Rixubis | coagulation factor IX [recombinant] | J7200 |
| Roctavian | valoctocogene roxaparvovec-rvox | J1412 |



* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

** Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to transplant@humana.com.

| Blood-clotting Factors | | |
|---------------------------------------|---|---------------|
| Brand medication name | Generic medication name | Billing Codes |
| SevenFact intravenous solution | coagulation factor VIIa (recombinant)-jncw; eptacog beta | J7212 |
| Tretten | coagulation factor XIII A-subunit [recombinant] | J7181 |
| Vonvendi | von Willebrand factor [recombinant] | J7179 |
| Wilate | von Willebrand factor / coagulation factor VIII complex [human] | J7183 |
| Xyntha ‡ | antihemophilic factor [recombinant] ‡ | J7185 |
| Xyntha Solofuse ‡ | antihemophilic factor [recombinant] ‡ | J7185 |



* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System (HCPCS) codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

** Step therapy required through a Humana-preferred drug as part of preauthorization.

†† Preauthorization requests will be reviewed by the Humana National Transplant Network and can be submitted by fax to 502-508-9300, by phone at 866-421-5663, Monday – Friday, 7 a.m. – 7 p.m., Central time, or by email to transplant@humana.com.